The bullish analysts believe that the approval of Denosumab is expected to provide significant encouragement to the company as its R&D pipeline has been unable to churn out a strong molecule for years and has continued to face a number of setbacks.  Most analysts believe the drug will be approved by mid-2010.  Moreover, data presented in July and August 2009 from skeletal related events (SRE) clinical trials showed that Denosumab is superior to the standard of care Zometa (Novartis).  Most of the analysts consider this news as highly positive for the company and believe that the drug has a multibillion dollar potential.  In addition to Denosumab, these analysts have increasing visibility for the rest of the pipeline, with many Phase II compounds addressing large markets, including diabetes, asthma, and cancer, which are expected to report data in 2010.  Moreover, the company has a strong balance sheet, which should provide significant strategic flexibility.